Education
About Us
Working with TipRanks
Follow Us
Cormedix (CRMD)
NASDAQ:CRMD
Earnings Data
Report Date
Aug 07, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
0.12Last Year’s EPS
-0.25Same Quarter Last Year
Strong Buy
Based on 6 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 06, 2025
|% Change Since: 23.59%
|Next Earnings Date:Aug 07, 2025
Earnings Call Sentiment|Positive
The earnings call for CorMedix presented a generally positive outlook with strong first-quarter sales, profitability, and optimistic revenue guidance for the first half of 2025. However, there were concerns regarding a predicted moderate revenue decline in Q2 and increased operating expenses. The initiation of a Phase 3 clinical study and an increase in cash reserves contribute to a positive sentiment.Company Guidance
During CorMedix's first quarter 2025 earnings call, the company provided updated guidance for DefenCath sales, projecting net revenue of approximately $70 million from existing purchasing customers over the first half of the year, with net sales in the first quarter reaching $39.1 million. Adjusted EBITDA for the quarter was $23.6 million, slightly surpassing earlier projections. CorMedix achieved profitability with a net income of $20.6 million, translating to $0.32 per share, compared to a net loss in the same period last year. The company anticipates a moderate sequential decline in revenue from Q1 to Q2 due to shipment timing but expects utilization growth in the latter half of 2025. Additionally, CorMedix is progressing with its Phase 3 clinical study for CLABSIs and anticipates completing the study by late 2026 or early 2027, with potential peak sales in the TPN indication estimated between $150 million to $200 million. The company also reported a cash position of $77.5 million as of March 31, 2025.Strong First Quarter Net Sales
CorMedix reported strong first quarter net sales of $39.1 million, consistent with earlier pre-announced results.
Profitability Achieved
CorMedix achieved profitability for the first quarter with a net income of $20.6 million, or $0.32 per share, compared to a net loss of $14.5 million in the first quarter of 2024.
Adjusted EBITDA Exceeds Expectations
The adjusted EBITDA for the first quarter of $23.6 million was slightly above the company's earlier pre-announcement.
Optimistic Revenue Guidance for First Half of 2025
CorMedix updated the net revenue guidance for DefenCath sales toward the upper end of the range, projecting approximately $70 million for the first half of the year.
Phase 3 Clinical Study Initiated
CorMedix has begun its Phase 3 clinical study for the reduction of central line-associated bloodstream infections, with the first site operational and screening patients.
Cash and Cash Equivalents Increase
The company has cash and cash equivalents of $77.5 million as of March 31, 2025, with net cash provided by operations during the first quarter of $19.7 million.
---
CRMD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
CRMD Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| May 06, 2025 | $9.03 | $11.16 | +23.59% |
| Mar 25, 2025 | $10.77 | $7.34 | -31.85% |
| Oct 30, 2024 | $12.97 | $10.05 | -22.51% |
| Aug 14, 2024 | $3.78 | $4.92 | +30.16% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Cormedix (CRMD) report earnings?
Cormedix (CRMD) is schdueled to report earning on Aug 07, 2025, TBA Not Confirmed.
What is Cormedix (CRMD) earnings time?
Cormedix (CRMD) earnings time is at Aug 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CRMD EPS forecast?
CRMD EPS forecast for the fiscal quarter 2025 (Q2) is 0.12.
---